Objective: Hyperglycemia worsens outcomes in critical illness. This randomized, double-blind, placebo-controlled clinical trial tested whether insulin treatment of hyperglycemia during cardiopulmonary bypass would reduce neurologic, neuroophthalmologic, and neurobehavioral outcomes after coronary artery bypass grafting.
A fter coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB), 6% of patients have adverse neurologic outcomes. 1 In the past, at least 50% of patients undergoing CPB displayed at least temporary deterioration in psychomotor performance, and a similar fraction of patients demonstrated biochemical evidence of neural injury. 2, 3 The incidence of frank stroke has been as frequent as 5% in some series. 2 Despite continuing investigation, fundamental questions remain unanswered. One of these questions, that of the value of prevention of hyperglycemia during CPB, was prompted by evidence linking adverse outcomes to intraoperative embolism and hyperglycemia to worsening ischemic neurologic injury. 4, 5 We therefore performed a randomized clinical trial in nondiabetic patients undergoing CABG to determine whether attempting to control hyperglycemia during CPB with insulin infusion, compared with placebo infusion, would reduce the combined incidence of new post-CABG neurologic, neuroophthalmologic, and neuropsychologic deficits. Secondarily, we sought to determine whether attempted blood glucose control during CPB would reduce the length of postoperative hospital stay. Some results unrelated to the primary hypothesis of this trial have been reported previously. [6] [7] [8] 
Methods
The study was reviewed and approved by the Wake Forest University School of Medicine Institutional Review Board. Written informed consent was obtained from each prospective research subject. All subjects were English-speaking adults between the ages of 35 and 80 years scheduled to undergo CABG with CPB. Subjects with a history of diabetes mellitus treated by diet, oral hypoglycemic agents, or insulin were excluded. Subjects with a history of a neurodegenerative disease (eg, Alzheimer or Parkinson disease), major depressive disorder, or psychosis in the past 5 years were also excluded. Subjects underwent a neurologic and neuro-ophthalmologic history and physical examination and also underwent neuropsychologic testing on the afternoon or evening before the operation. These examinations usually were conducted in the patient's hospital room by one of two nurse clinicians. Generally, the same examiner conducted all examinations of a given subject.
Day of the Operation
All subjects were premedicated with morphine, 0.1 mg · kg Ϫ1 administered intramuscularly, and, in most cases, oral lorazepam, 50 g · kg Ϫ1 . Anesthesia consisted of intravenous fentanyl, 25 to 50 g · kg Ϫ1 , and midazolam, 0.1 to 0.3 mg · kg Ϫ1 . After neuromuscular blockade (in most cases intravenous pancuronium, 0.1-0.15 mg · kg Ϫ1 ), intubated subjects were ventilated with oxygenenriched air. Enflurane at inhaled concentrations of 1% or less was sometimes used to supplement general anesthesia. Intraoperative hemodynamic aberrations were treated according to protocol with intravenous fluid, vasodilators, vasoconstrictors, positive inotropes, atropine, or ␤-adrenergic blockers, as appropriate. No intravenous dextrose was administered intraoperatively on a routine basis. Dextrose was present in cardioplegic solutions (see Table  E1 ). Corticosteroids were not administered to these patients.
Blood Glucose Control
Arterial blood samples were obtained at 15-minute intervals during CABG to measure blood glucose concentrations with a handheld glucose meter (Accucheck; Roche Diagnostics, Basel, Switzerland). In the control arm, blood glucose concentrations were measured and recorded for later analysis. A saline infusion was periodically adjusted to preserve blinding. For subjects randomized to blood glucose control, after induction of anesthesia, insulin infusion at 2 U/h in a 70-kg patient was started when the blood glucose concentration exceeded 100 mg/dL. If 2 U/h failed to reduce the blood glucose concentration to approximately 100 mg/dL, the dosage was increased by 50% (to 3 U/h) or 100% of the beginning dose (to 4 U/h). Insulin infusion was adjusted as required at 15-minute intervals by the study nurse. Only the study nurse was aware of the glucose concentrations or whether insulin was being infused. When blood glucose concentrations decreased to less than 100 mg/dL, the insulin infusion was discontinued. When blood glucose concentrations decreased to less than 70 mg/dL, 100 to 200 mL of dextrose 5% was administered at the direction of the study nurse. After the patient was weaned from CPB, the insulin infusion was weaned over 30 to 45 minutes. Serum potassium concentrations were measured every 30 minutes intraoperatively and were maintained between 3.5 and 5.5 mEq/L.
CPB was conducted with a membrane oxygenator and a buffered crystalloid priming solution to which no glucose was added. Mean arterial pressure was pharmacologically maintained between 50 and 90 mm Hg. Subjects were cooled to a core temperature of 27°C and then rewarmed to 37.5°C. The left ventricle was vented through the right superior pulmonary vein, and the aorta was vented (when indicated) through a needle vent. Arterial inflow and cardiotomy suction filters were used. PaO 2 was maintained at 150 to 200 mm Hg, and PaCO 2 was maintained at 38 to 42 mm Hg by the alpha-stat approach. Either crystalloid or (more commonly) blood cardioplegic solution was delivered antegradely. Cardioplegia components are described in Table E1 . During rewarming, the inflow blood temperature never exceeded 38.5°C, and the gradient between inflow blood temperature and core temperature never exceeded 10°C.
Outcome Measurement Timing
A brief screening neurologic examination was conducted to document neurologic events that occurred on postoperative days 1 to 4. Subjects underwent a final, in-hospital, full neurologic, neuroophthalmologic, and neuropsychologic evaluation between postoperative days 4 and 8. Subjects underwent the full neurologic, neuro-ophthalmologic, and neuropsychologic battery at 1 month (3-6 weeks) and again at 5.5 to 6.5 months. This testing took place in a quiet office.
Primary Outcome
The primary outcome variable used to define treatment effect in this clinical trial was any new or worsening neurologic or neuroophthalmologic deficit, neurologic death, or a decrease of at least 20% in 2 or more neuropsychologic test results at the 4-to 8-day postoperative examination.
Comprehensive Neurologic Examination
The comprehensive neurologic and neuro-ophthalmologic examination was performed by a certified neurologic nurse clinician and confirmed by a neurologist. On postoperative days 4 to 8, at 3 to 6 weeks, and at 5.5 to 6.5 months postoperatively, the entire neurologic examination was repeated, and results were scored according to the National Institutes of Health stroke scale and Stroke Data Bank criteria.
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Neuropsychologic Assessment
We defined clinically important deterioration in performance as an individual subject's decrease from preoperative to postoperative score of 20% 10,11 on a test. Neuropsychologic evaluation was performed preoperatively, on postoperative days 4 to 8, at 3 to 6 weeks, and at 5.5 to 6.5 months. The standard neuropsychologic battery was used. The Visual Reaction Time test was used only to discriminate between deterioration in performance because of ischemic neurologic deficits from deterioration caused by visual impairment.
Sample Size Calculations
We anticipated that at least 50% of the patients would experience one or more of these deficits at the 4-to 8-day assessment. A sample size of 186 in each group was necessary to detect a 17% difference in deficits (0.5 to 0.33 or 0.5 to 0.67) with 90% power at the 5% 2-sided level of significance.
Patients were randomized to the treatment groups with equal probability by blocked randomization. Block sizes of varying length were determined randomly. Treatment assignments were generated by a randomization computer program.
Statistical Testing
The primary outcome was compared in the 2 groups by the Fisher exact test or the 2 test where appropriate. Blood glucose measurements were compared over time by a mixed-effects, repeatedmeasures model. SAS (version 8; SAS Institute, Cary, NC) was used for all calculations.
Interim Monitoring
An independent Data Safety and Monitoring Board met once a year to examine interim results. Statistical guidelines (on the basis of modifications of procedures discussed by O'Brien and Fleming 12 and Lan and colleagues 13 ) were used during the interim reviews.
Results
A total of 381 subjects completed preoperative screening and neuropsychologic evaluations and were enrolled in the study. The 2 groups were well matched on the basis of sex, age, and race, as shown in Table 1 . Subjects in the 2 study groups were distributed similarly by operating surgeon (Table 1) .
Baseline medical characteristics were similar in the 2 groups, with the exception of a more frequent history of congestive heart failure in the insulin-treated group (9.6% vs 4.2%). A history of cerebrovascular disease was present in 16.6% of placebo-treated patients and 15.4% of insulintreated patients. Five percent of patients in both groups demonstrated a stenosis of greater than 50% in one or more of the right or left, internal, or common carotid arteries by Doppler examination. The preoperative neuropsychologic examination scores were similar in the 2 treatment arms. There were no significant between-group differences (Table  E2) . Few subjects in either group had preoperative neuroophthalmologic or neurologic abnormalities (Table E3) .
The duration of CPB (121 Ϯ 36 vs 125 Ϯ 37 minutes) and the duration of aortic clamping (57 Ϯ 22 vs 59 Ϯ 22 minutes) were similar in the placebo-and insulin-treated groups, respectively. Most patients (80% of placebo-treated and 82% of insulin-treated patients) received blood cardioplegia. The remainder received crystalloid cardioplegia.
All patients in the insulin-treated group demonstrated a blood glucose concentration of greater than 100 mg/dL and received insulin. Blood glucose concentrations were maintained at significantly (P Ͻ .01) reduced values in the insulin-treated group compared with those in the placebotreated group, as shown in Figure 1 . Initial blood glucose concentrations on arrival in the intensive care unit (ICU) were similar in the placebo-treated and insulin-treated groups (179 Ϯ 60 vs 178 Ϯ 57 mg/dL, respectively). One patient in the placebo-treated group and no patients in the insulin-treated group had a blood glucose measurement of less than 80 mg/dL in the first 24 hours in the ICU. During the first 24 hours in the ICU, all patients had a blood glucose measurement of at least 100 mg/dL. Many patients had at least one blood glucose measurement of greater than 200 mg/dL (placebo-treated group, 40%; insulin-treated group, 42%). Only a few patients had at least one blood glucose measurement of greater than 300 mg/dL (placebo-treated group, 8%; insulin-treated group, 6%). One percent of patients in both groups had at least one blood glucose measurement of greater than 400 mg/dL during the first 24 hours in the ICU.
Most adverse events (including death) had a similar incidence in the 2 groups (Table 2) . During postoperative evaluations, the 2 groups were similar (Table 3) . Neuroophthalmologic, neurologic, and neuropsychologic deficits were most common at the 4-to 8-day examination and less common thereafter (Table 4 ). There was no significant between-group difference in the primary outcome (Table 4) .
Length of stay was similar in the 2 groups (median of 6 days and range of 3-85 days in the placebo-treated group and median of 7 days and range of 3-51 days in the insulintreated group). The total number of emboli counted ultrasonically in the left common carotid artery was similar in the 2 groups (median of 105 and range of 1-2563 in the placebo-treated group and median of 108 and range of 1-14,613 in the insulin-treated group).
To determine whether increasing blood glucose concentrations per se might associate with worsening neurologic outcomes, we divided subjects in the placebo-treated group into 2 equal classes on the basis of the degree of hyperglycemia they demonstrated during CPB. The cutoff point between the 2 groups was determined by calculating the area under the blood glucose versus time curve for each placebo-treated subject and then rank ordering them. We found that subjects ranked in the upper 50% of ranks for areas under the curve (these were the patients with more consistently increased blood glucose measurements) were no more likely than those in the lower 50% of ranks to have new or worsening neurologic, neurophthalmologic, or neurobehavioral deficit or neurologic death (68% vs 71% at 4-8 days, 37% vs 42% at 5.5-6.5 weeks, and 22% vs 28% at 5.5-6.5 months, respectively).
Discussion
Administration of insulin during CPB failed to improve outcomes, as assessed by the combined incidence of neuroophthalmologic, neurologic, or neuropsychologic deficits or neurologic death in patients without diabetes mellitus undergoing CABG. Insulin administration failed to improve either short-term or long-term outcome and failed to reduce length of hospital stay. Moreover, in the control group, subjects with greater blood glucose measurements during CPB had no worse outcome than subjects with more nearly normal blood glucose measurements.
We were unable to completely prevent hyperglycemia during CPB, despite insulin infusion. It is likely that we would have achieved better glucose control had we administered larger doses of insulin in response to hyperglycemia. Studies completed after we initiated this protocol have shown that attempting complete glucose control during CPB might be hazardous because of the frequent postoperative hypoglycemia and hypokalemia that will result. 14 Our selection of 100 mg/dL as our target value was based on the diabetes literature. Since the results of the Diabetes Control and Complications Trial were published, there has been an increased emphasis on avoidance of hyperglycemia in diabetic subjects. 15 Our negative results do not argue against tight control of blood glucose before or after CPB. 16, 17 Numerous studies have shown value in the control of hyperglycemia in patients undergoing CABG and with other critical illnesses. [18] [19] [20] Some recent studies also demonstrate an association between hyperglycemia and adverse outcomes after ischemic stroke. 21 Our data argue that blood glucose concentrations as great as 200 mg/dL do not appear to be deleterious during CPB in nondiabetic patients. Thus, aggressive treatment does not appear to be warranted. These results and conclusions are consistent with an earlier study of glucose-insulin-potassium (GIK) during CABG. 22 Nevertheless, our study has several obvious limitations. We made no attempt to control blood glucose concentrations at times other than CPB in these subjects who did not have diabetes. We hypothesized that brain injury associated with coronary surgery occurs mostly during CPB, and we focused on control of blood glucose during that critical period. It very well could be important to control blood glucose concentrations after CPB in patients who have sustained a brain insult, and our results do not address that possibility. We also did not study patients having any of the several forms of "beating-heart" surgery without CPB, and our results might not apply to those patients. After this study was completed, our usual practice changed, and we no longer routinely cool patients who are undergoing CABG. It is possible that tight glucose control might offer greater benefit to patients having lesser degrees of hypothermic protection. On the other hand, a recent study of patients undergoing correction of congenital heart disease has shown no detrimental effect on outcome of increased intraoperative blood glucose concentrations. 23 The most important limitation of our study is that we specifically excluded diabetic patients from our study, and therefore our results might not apply to that population. Diabetes is associated with worse outcomes after CABG. 24 We suggest that insulin infusion should be used to control blood glucose concentrations in diabetic subjects undergoing CABG. Our exclusion of diabetic subjects led to a disproportionate reduction in the number of female subjects.
A recent study has compared tight glycemic control with infusion of GIK solution to intermittent subcutaneous injections of insulin in diabetic patients undergoing CABG. 25 In this trial 30% of these diabetic patients were using insulin, and the remainder were using either oral agents or dietary adjustments for glucose control preoperatively. In this study GIK was discontinued on initiation of CPB and not restarted until the aorta was unclamped. In other words, it studied GIK at times (27) All data are given as percentage incidence (no. of observations).
when we did not infuse insulin and did not infuse GIK at the specific times we infused insulin. Moreover, this trial focused on those patients who were excluded from our study. Interestingly, the GIK group had a reduced incidence of atrial fibrillation, a shorter length of hospital stay, and a survival advantage compared with the control group. Our outcome measures are similar to those used in other tests of neuroprotective drugs and neuroprotective strategies during cardiac surgery. [26] [27] [28] Our selection of neuropsychologic tests was consistent with recommendations from consensus panels. 29 Our criterion for neuropsychologic deficit defines a distinctly abnormal score for each subject on the basis of the subject's baseline performance. Because of learning-practice effects, it would be expected that healthy control subjects not having operations would show at worst the same score as at baseline and more often an improved score.
In conclusion, insulin infusion for attempted blood glucose control during CPB failed to improve either short-term or long-term neurologic outcomes, and it failed to shorten length of stay. Even though tight control of blood glucose concentration improves outcomes in many classes of patients with critical illness, attempted tight control of blood glucose with insulin infusion appears not to produce brain protection in patients undergoing CABG with CPB. Perhaps the opinion expressed in a recent editorial by Loepke and Spaeth, 30 that children are unlike adults in the failure of hyperglycemia to worsen outcome, might be incorrect. It might be that neither adults nor children derive benefit from strategies to prevent mild intraoperative hyperglycemia in patients who do not have diabetes mellitus. *Maximum n for each treatment arm; n varies by no more than 6 because of missing values (except for Trails B, in which n ϭ 175 for arm 1 and n ϭ 173 for arm 2, and for Rey, in which n ϭ 175 for arm 1 and n ϭ 174 for arm 2). 
